Netflix's 'The Whisper Man' Dominates Weekly Movie Chart with 47.5% Share
Analysis Daniel Marsh

Netflix's 'The Whisper Man' Dominates Weekly Movie Chart with 47.5% Share

Netflix's 'The Whisper Man' captured 47.5% of top-10 English film views in early September, raising questions about content depth. Investors eye upcoming chart trends.

NFLX
Nokia's EURO STOXX 50 Debut: A Trade Setup for Sept. 18
Markets Daniel Marsh

Nokia's EURO STOXX 50 Debut: A Trade Setup for Sept. 18

Nokia's addition to the EURO STOXX 50 on Sept. 21 sets up a Sept. 18 rebalancing window, but the stock's AI-driven fundamentals, not index flows, will define its long-term value.

VGK
Celestica's Growth Strategy Faces Customer Concentration Test
Analysis Daniel Marsh

Celestica's Growth Strategy Faces Customer Concentration Test

Celestica's CFO becomes growth president as AI infrastructure revenue surges, but top-3 customers drive 63% of Q2 sales. Can the new structure diversify?

CLS
Loonie Under Pressure as BoC, Fed Signals Loom
Forex Rebecca Torres

Loonie Under Pressure as BoC, Fed Signals Loom

The Canadian dollar weakened to C$1.3866 per USD ahead of twin central bank signals Wednesday. BoC minutes and Fed rate decision could set the tone for the loonie.

FXI USO GLD
RTX 5090 Street Price Soars, But Nvidia's Books Tell a Different Story
Analysis Daniel Marsh

RTX 5090 Street Price Soars, But Nvidia's Books Tell a Different Story

RTX 5090 street prices hit $5,000, but Nvidia only books $1,999 per card. The premium reflects scarcity, not revenue, with Graphics segment at 8.2% of sales.

NVDA
Proposed H-1B Rule Could Raise Costs and Delays in Tech Layoffs
Regulation James Calloway

Proposed H-1B Rule Could Raise Costs and Delays in Tech Layoffs

A proposed DHS rule would end the 60-day H-1B grace period, potentially increasing costs and delays for tech employers during layoffs and rehiring.

MSFT
AstraZeneca's SERENA-4 Flop Limits Etcamah's First-Line Reach
Analysis Daniel Marsh

AstraZeneca's SERENA-4 Flop Limits Etcamah's First-Line Reach

AstraZeneca's SERENA-4 trial failed to show a significant PFS benefit for Etcamah in first-line breast cancer, narrowing its commercial opportunity to ESR1-mutant patients.

AZN
onsemi Investor Day: Synaptics Deal and Margin Recovery in Focus
Analysis Daniel Marsh

onsemi Investor Day: Synaptics Deal and Margin Recovery in Focus

onsemi's Investor Day on Wednesday will test whether Friday's 8.5% stock rally can be sustained as management details its $7B Synaptics acquisition and margin recovery plan.

ON
Apple's iPhone 18 Pro Max Price Hike: A $1,299 Test of Consumer Demand
Technology Sarah Chen

Apple's iPhone 18 Pro Max Price Hike: A $1,299 Test of Consumer Demand

Apple's $1,299 iPhone 18 Pro Max carries an 8.3% price increase, allowing unit sales to fall 7.7% before revenue dips. Preorders begin Saturday, with margins and consumer demand in focus.

AAPL
Broadcom's AI Bet: $126.8B Purchase Pledges Signal Deep Customer Ties
Earnings James Calloway

Broadcom's AI Bet: $126.8B Purchase Pledges Signal Deep Customer Ties

Broadcom's latest filing shows $126.8B in purchase commitments, 1.8x nine-month revenue, plus a $29B lease backstop, underscoring AI-fueled expansion and concentration risks.

AVGO
TKO Stock Awaits Mexico City Revenue Data as WWE Expands Globally
Analysis Daniel Marsh

TKO Stock Awaits Mexico City Revenue Data as WWE Expands Globally

WWE's Mexico City return showcased a title change, but TKO Group hasn't released revenue figures. Investors await financial data to gauge international expansion value.

TKO
Gamma Shares Hold Premium as Waterland Weighs Solo Bid
Markets Daniel Marsh

Gamma Shares Hold Premium as Waterland Weighs Solo Bid

Gamma shares closed at £11.40, 1.8% above Epiris's offer, as investors bet on a possible higher bid from Waterland, which remains interested after splitting from Giacom.